[1]阮义生 朱梅 郭亮 唐勇.Galectin-3、CK-19、MiRNA221对细针穿刺标本中BRAFV600E阴性及细胞病理不确定甲状腺结节的诊断价值[J].国际内分泌代谢杂志,2023,43(05):396-400.[doi:10.3760/cma.j.cn121383-20220611-06025]
　Ruan Yisheng,Zhu Mei,Guo Liang,et al.Diagnostic value of Galectin-3、CK-19 and MiRNA221 in thyroid nodule with indeterminate FNAC and negative BRAFV600E[J].International Journal of Endocrinology and Metabolism,2023,43(05):396-400.[doi:10.3760/cma.j.cn121383-20220611-06025]
点击复制

Galectin-3、CK-19、MiRNA221对细针穿刺标本中BRAFV600E阴性及细胞病理不确定甲状腺结节的诊断价值()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年05期
页码:
396-400
栏目:
论著
出版日期:
2023-09-20

文章信息/Info

Title:
Diagnostic value of Galectin-3、CK-19 and MiRNA221 in thyroid nodule with indeterminate FNAC and negative BRAFV600E
作者:
阮义生1 朱梅1 郭亮1 唐勇2
1合肥市第八人民医院内分泌科,合肥 238000; 2合肥市第八人民医院病理科,合肥 238000
Author(s):
Ruan Yisheng1;  Zhu Mei1;  Guo Liang1;  Tang Yong2.
1Department of Endocrinology, Hefei Eighth People's Hospital, Hefei 238000, China; 2Department of Pathology, Hefei Eighth People's Hospital, Hefei 238000, China
关键词:
甲状腺结节;  细胞角蛋白19片段;  半乳糖凝集素-3;  微小RNA221
Keywords:
Thyroid nodule;  Cytokeratin 19;  Galectin-3;  MicroRNA221
DOI:
10.3760/cma.j.cn121383-20220611-06025
摘要:
目的 探讨半乳糖凝集素-3(Gal-3)、细胞角蛋白19片段(CK-19)及微小RNA221(MiR221)对BRAFV600E阴性、细胞病理(TBSRTC)Ⅲ～Ⅴ类甲状腺结节的诊断价值。方法 回顾我院甲状腺结节手术治疗的患者资料。以术后组织病理为金标准,建立基于二分类变量的决策树模型。分析模型、3种标记物单独或组合后的受试者工作特征曲线(ROC),比较曲线下面积(ROCAUC)的差异。结果 纳入甲状腺结节115例,恶性46例,良性69例。Gal-3、CK-19和MiR221的ROCAUC分别为0.808、0.848、0.669; 两个标记物阳性(组合1)和3个均阳性(组合2)的ROCAUC分别为0.873,0.812; CK-19、Gal-3和TBSRTC进入决策树模型,模型ROCAUC=0.942。两两比较后,决策树模型、MiR221 ROCAUC与其他ROCAUC差异均有统计学意义(P≤0.05); CK-19、Gal-3、组合1及组合2之间的ROCAUC差异均无统计学意义(P>0.05)。结论 CK-19、Gal-3和TBSRTC对BRAFV600E阴性及细胞病理不确定恶性甲状腺结节具有较高的诊断价值。
Abstract:
Objective To investigate the diagnostic value of Galectin-3(Gal-3), Cytokeratin 19(CK-19)and MicroRNA221(MiR221)in TBSRTCⅢ-Ⅴ thyroid nodule with negative BRAFV600E.Methods Data of patients who undergoing thyroid nodule surgery in our hospital were retrospectively analyzed. Taking postoperative histopathology as the diagnostic standard, a dichotomous decision tree model was established. Receiver operating characteristic curves(ROC)of the model and the markers alone or combination were analyzed, and the area under the ROC(ROCAUC)was compared in pairs.Results Among 115 cases, 46 were malignant and 69 were benign. ROCAUC of Gal-3, CK-19 and MiR221 was 0.808, 0.848 and 0.669, respectively. ROCAUC of two positive markers(combination 1)and three positive(combination 2)was 0.873, 0.812, respectively. CK-19, Gal-3 and TBSRTC entered the model, and the ROCAUC was 0.942. After paired comparison of ROCAUC, the model and MiR221 was significantly different(P≤0.05)from others, respectively; the difference, between CK-19, Gal-3, combination 1 and combination 2, was not statistically significant(P>0.05).Conclusion CK-19, Gal-3 and TBSRTC Combination has a high diagnostic value in TBSRTC Ⅲ-Ⅳ thyroid nodule with negative BRAFV600E.

参考文献/References:

[1] Attia AS,Hussein M,Issa PP,et al.Association of BRAFV600E mutation with the aggressive behavior of papillary thyroid microcarcinoma:a meta-analysis of 33 studies[J].Int J Mol Sci,2022,23(24):15626.DOI:10.3390/ijms232415626.
[2] Cibas ES,Ali SZ.The 2017 Bethesda system for reporting thyroid cytopathology[J].Thyroid,2017,27(11):1341-1346.DOI:10.1089/thy.2017.0500.
[3] 田勍,洪天配.甲状腺结节诊治过程中的难点与应对[J].国际内分泌代谢杂志,2021,41(6):557-561.DOI:10.3760/cma.j.cn121383-20210727-07074.
[4] 王欢,陈昶,姜勇,等.免疫标记和BRAF V600E突变联合检测在细胞学诊断不确定甲状腺结节中的应用[J].成都医学院学报,2022,17(1):52-57.DOI:10.3969/j.issn.1674-2257.2022.01.012.
[5] 中华医学会超声医学分会浅表器官和血管学组,中国甲状腺与乳腺超声人工智能联盟.2020甲状腺结节超声恶性危险分层中国指南:C-TIRADS[J].中华超声影像学杂志,2021,30(3):185-200.DOI:10.3760/cma.j.cn131148-20210205-00092.
[6] Prasad PA,Raju K.Diagnostic utility of CK19 and galectin-3 in differentiating papillary thyroid carcinoma from nonneoplastic lesions of thyroid[J].J Cancer Res Ther,2022,18(3):644-649.DOI:10.4103/jcrt.jcrt_563_21.
[7] Bartolazzi A,Orlandi F,Saggiorato E,et al.Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology:a prospective multicentre study[J].Lancet Oncol,2008,9(6):543-549.DOI:10.1016/S1470-2045(08)70132-3.
[8] Ramkumar S,Sivanandham S.The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma[J].Cureus,2021,13(12):e20339.DOI:10.7759/cureus.20339.
[9] 张霖雷,付延英,申伟,等.微小RNA-221对甲状腺癌细胞侵袭能力的影响及其机制[J].中华实验外科杂志,2021,38(5):829-831.DOI:10.3760/cma.j.cn421213-20200608-01193.
[10] 林在楷,周琨,陆霁,等.ROC曲线分析miRNA-221/222作为侵袭性甲状腺乳头状癌诊断标志物的临床价值[J].癌症进展,2018,16(1):49-52.DOI:10.11877/j.issn.1672-1535.2018.16.01.14.

相似文献/References:

[1]杨成会,缪珩.二甲双胍在甲状腺疾病治疗中的作用[J].国际内分泌代谢杂志,2015,(04):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
　Yang Chenghui,Miao Heng..Roles of metformin in the treatment of thyroid diseases[J].International Journal of Endocrinology and Metabolism,2015,(05):255.[doi:10.3760/cma.j.issn.1673-4157.2015.04.011]
[2]梁绮君 余寿益 李淑华 胡晨鸣 杨焱.甲状腺结节与代谢综合征的相关性研究[J].国际内分泌代谢杂志,2015,(05):293.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.002]
　Liang Qijun,Yu Shouyi,Li Shuhua,et al.Association of thyroid nodule and metabolic syndrome[J].International Journal of Endocrinology and Metabolism,2015,(05):293.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.002]
[3]郑仁东 张会峰 胡咏新 曹雯 曹琳 孙洪平 褚晓秋 刘克冕 刘超.男性2型糖尿病患者甲状腺结节 与内分泌激素的相关性研究[J].国际内分泌代谢杂志,2018,38(04):222.[doi:10.3760/cma.j.issn.1673-4157.2018.04.002]
　Zheng Rendong,Zhang Huifeng,Hu Yongxin,et al.Association of thyroid nodules with endocrine hormones in male patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2018,38(05):222.[doi:10.3760/cma.j.issn.1673-4157.2018.04.002]
[4]陈茉 徐书杭 刘超.良性甲状腺结节的热消融治疗进展[J].国际内分泌代谢杂志,2019,39(04):248.[doi:10.3760/cma.j.issn.1673-4157.2019.04.008]
　Chen Mo,Xu Shuhang,Liu Chao.Advancement of thermal ablation on benign thyroid nodules[J].International Journal of Endocrinology and Metabolism,2019,39(05):248.[doi:10.3760/cma.j.issn.1673-4157.2019.04.008]
[5]周一帆 季沁 陈国芳 褚晓秋 陈茉 丁文波 胡欣 相萍萍 曾铮 王建华 徐书杭 刘超.TI-RADS对细胞学结果不确定甲状腺结节的诊断价值[J].国际内分泌代谢杂志,2019,39(04):226.[doi:10.3760/cma.j.issn.1673-4157.2019.04.003]
　Zhou Yifan,Ji Qin,Chen Guofang,et al.Clinical value of TI-RADS in the diagnosis of thyroid nodules with indeterminate cytology[J].International Journal of Endocrinology and Metabolism,2019,39(05):226.[doi:10.3760/cma.j.issn.1673-4157.2019.04.003]
[6]周一帆 王建华 徐书杭.甲状腺细胞病理学Bethesda报告系统的更新及研究进展[J].国际内分泌代谢杂志,2020,40(03):175.[doi:10.3760/cma.j.issn.1673-4157.2020.03.007]
　Zhou Yifan,Wang Jianhua,Xu Shuhang.Update and research progress of the Bethesda system for reporting thyroid cytopathology[J].International Journal of Endocrinology and Metabolism,2020,40(05):175.[doi:10.3760/cma.j.issn.1673-4157.2020.03.007]
[7]杨晶晶,徐书杭,刘超.针穿活检用于甲状腺结节诊断的研究进展[J].国际内分泌代谢杂志,2021,41(01):20.[doi:10.3760/cma.j.cn121383-20200511-05018]
　Yang Jingjing,Xu Shuhang,et al.Update on core needle biopsy in the diagnosis of thyroid nodules[J].International Journal of Endocrinology and Metabolism,2021,41(05):20.[doi:10.3760/cma.j.cn121383-20200511-05018]
[8]田勍,洪天配.甲状腺结节诊治过程中的难点与应对[J].国际内分泌代谢杂志,2021,41(06):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
　Tian Qing,Hong Tianpei..Difficulties and countermeasures in the diagnosis and treatment of thyroid nodules[J].International Journal of Endocrinology and Metabolism,2021,41(05):557.[doi:10.3760/cma.j.cn121383-20210727-07074]
[9]张雅,相萍萍,徐书杭,等.经皮无水乙醇注射治疗甲状腺结节:老方法的新认识[J].国际内分泌代谢杂志,2022,42(06):469.[doi:10.3760/cma.j.cn121383-20210926-09075]
　Zhang Ya,Xiang Pingping,Xu Shuhang,et al.Percutaneous ethanol ablation for thyroid nodules: new perspectives on an old paradigm[J].International Journal of Endocrinology and Metabolism,2022,42(05):469.[doi:10.3760/cma.j.cn121383-20210926-09075]
[10].甲状腺结节和分化型甲状腺癌诊治指南(第二版)[J].国际内分泌代谢杂志,2023,43(02):149.[doi:10.3760/cma.j.cn311282-20221023-00589]
　Chinese Society of Endocrinology,Thyroid and Metabolism Surgery Group of the Chinese Society of Surgery,China Anti-Cancer Association,et al.Guidelines for the Diagnosis and Management of Thyroid Nodules and Differentiated Thyroid Cancer(Second Edition)[J].International Journal of Endocrinology and Metabolism,2023,43(05):149.[doi:10.3760/cma.j.cn311282-20221023-00589]

备注/Memo

备注/Memo:
通信作者:阮义生,Email:chinafeng24@126.com
更新日期/Last Update: 2023-10-10